Mitochondria-targeted graphene for advanced cancer therapeutics

Tanveer A Tabish1, Roger J Narayan2

  • 1UCL Cancer Institute, University College London, London, Bloomsbury WC1E 6DD, UK.

Acta Biomaterialia
|May 9, 2021
PubMed

Insights

Mitochondria-targeted graphene (mitoGRAPH) offers a promising strategy to overcome challenges in cancer therapy. This nanotechnology enables selective drug delivery to cancer cell mitochondria, enhancing treatment efficacy and safety.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Classical chemotherapy faces challenges with non-specificity and drug resistance.
  • Mitochondria play crucial roles in cancer progression and are a target for novel therapies.
  • Current nanoparticle-based drug delivery systems for mitochondria have limitations in clinical application.

Purpose of the Study:

  • To review the design and development of mitochondria-targeted graphene (mitoGRAPH) for cancer therapy.
  • To explore the potential of mitoGRAPH in selectively targeting cancer mitochondria.
  • To provide insights into strategies for preparing mitoGRAPH for targeted destruction of cancer mitochondria.

Main Methods:

  • Review of existing literature on nanotechnology-driven mitochondrial therapies.
  • Focus on the design principles and preparation strategies for mitoGRAPH.
  • Analysis of mitoGRAPH's application in various therapeutic modalities.

Main Results:

  • Graphene emerges as a potent agent for safe and targeted delivery to tumor mitochondria.
  • mitoGRAPH shows potential in chemotherapy, photodynamic therapy, photothermal therapy, and combination therapies.
  • Nanoparticle-based approaches demonstrate efficacy in preclinical models but face challenges.

Conclusions:

  • Mitochondria-targeted therapy, particularly using mitoGRAPH, represents a significant advancement in cancer treatment.
  • mitoGRAPH has the potential to transform therapeutic interventions by precisely targeting cancer mitochondria.
  • Further research into mitoGRAPH development and application is warranted for clinical translation.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
16.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K